The STEADFAST clinical study of TX200 is the first-in-human trial to evaluate a CAR-Treg cell therapy BRISBANE, Calif.–(BUSINESS WIRE)–Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the United Kingdom’s (UK)...
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Range of VK2809 Doses for up to 52 Weeks SAN DIEGO, Nov. 19, 2019 /PRNewswire/ — Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on...
Westport, CT, Nov. 21, 2019 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full...
COPE-WEL study aims to validate Headstart® test for early detection and monitoring of pulmonary exacerbation of COPD • Headstart is a non-invasive self-test that detects lung biomarkers in the urine • Observational, multi-centre validation trial carried out in...
HOPKINTON, Mass., Nov. 20, 2019 (GLOBE NEWSWIRE) — Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today...
Email
Text